Proteome Sciences PLC Appointment of CEO (7786Z)
June 01 2016 - 2:01AM
UK Regulatory
TIDMPRM
RNS Number : 7786Z
Proteome Sciences PLC
01 June 2016
PRESS RELEASE
Proteome Sciences plc
(the "Company" or the "Group")
CEO Appointment
1(st) June 2016
Proteome Sciences is pleased to announce the appointment of
Jeremy Haigh as a director and CEO of the Company on 1(st) June
2016 as indicated in the press release to shareholders dated 18(th)
May 2016. He is a strong advocate of Precision Medicine and will
bring numerous industry contacts and considerable commercial
experience to the role.
Jeremy is an established leader in the biopharmaceutical sector
with 30 years in clinical and operational research and development,
principally at Merck and Amgen where most recently he was European
Chief Operating Officer, R&D.
His basic training was in neuropharmacology and he has been
significantly involved in healthcare policy and government affairs
in the UK and Europe having served on the board of the BioIndustry
Association (BIA), the European Federation of Pharmaceutical
Industries (EFPIA) Research Directors Group, and the Association of
the British Pharmaceutical Industry Innovation Board (ABPI). He is
currently the Chairman of Cogent Skills Limited and a member of
Imperial College Health Partners Advisory Council.The following
information regarding the appointment of Jeremy Rupert Michael
Haigh, aged 55 , is disclosed under Schedule 2(g) of the AIM Rules
for Companies:
Current directorships Former directorships and/or
and/or partnerships: partnerships (within the
last 5 years):
Cogent SSC Ltd Amgen Ltd
BioIndustry Association
Biovex Ltd
Amgen Research (Munich)
GmbH
Onyx Pharmaceuticals (UK)
Ltd
Mr. Haigh does not currently hold any ordinary shares in the
Company. There are no other disclosures required in relation to
Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for
Companies
With the news of his appointment, Jeremy Haigh commented,
"I am delighted to be joining Proteome Sciences at a time of
tremendous opportunity. The challenge of developing more precise
therapeutics coupled with growing patient expectations is creating
a highly receptive environment for our enabling technologies and I
look forward to working with the board and the entire team to
realise this potential."
Christopher Pearce added,
"As Chairman, I look forward to working closely with Jeremy and
the executive team to help them exploit the considerable commercial
opportunities arising in Precision Medicine from the outstanding
proteomics platform Proteome Sciences has established to deliver
truly personalised medicine."
ENDS
For further information please contact:
Proteome Sciences plc
Christopher Pearce, Executive
Chairman
Dr. Ian Pike, Chief Operating Tel: +44 (0)1932 865065
Officer
Geoff Ellis, Finance Director
finnCap Limited (nominated
adviser & broker) Tel : +44 (0)20 7220
Geoff Nash/James Thompson 0500
Public Relations
IKON Associates Email: adrian@ikonassociates.com
Adrian Shaw Tel: +44 (0)1483 271291
Mobile +44(0)7979 900733
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
With its HQ in Cobham, UK and laboratory facilities in London
and Frankfurt, Proteome Sciences is a global leader in applied
proteomics offering high sensitivity, proprietary technologies and
workflows in cell signalling pathways (SysQuant(R),
TMTcalibrator(TM)) and in protein biomarker discovery, validation
and assay development.
PS Biomarker Services(R) provides proteomics outsourcing
services and proprietary biomarker assays from its ISO 9001: 2008
facility in Frankfurt, Germany to pharmaceutical, biotechnology,
diagnostics companies and academia.
Proteome Sciences' research has discovered a large number of
novel protein biomarkers in key human diseases with a focus mainly
in neurological/neurodegenerative conditions and in cancer. It has
patented blood biomarkers in Alzheimer's disease, stroke, brain
damage and cancers for diagnostic and treatment applications that
are available for licenses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAZFLFXQEFXBBE
(END) Dow Jones Newswires
June 01, 2016 02:01 ET (06:01 GMT)